Heart failure with preserved ejection fraction (HFpEF) is a prevalent and multifaceted clinical syndrome, often underdiagnosed due to its heterogeneous presentation and overlapping comorbidities. Recent randomized trials have demonstrated the efficacy of sodium-glucose co-transporter 2 (SGLT2) inhibitors in reducing heart failure hospitalizations and cardiovascular mortality. In this review, we analyze the main challenges of HFpEF diagnosis and discuss current diagnostic algorithms. Based on recent evidence and recommendations, we propose a possible way to simplify and accelerate the diagnostic process of HFpEF, to support an early initiation of disease-modifying therapies. An interactive web-based version of the proposed algorithm is available at www.hfpefdiagnosis.com for research or exploratory purposes.
Current challenges for the diagnosis of HFpEF and possible simplification of the diagnostic approach / Bernardi, Marco; Golino, Michele; Spadafora, Luigi; Sarto, Gianmarco; Forte, Maurizio; Simeone, Beatrice; Rocco, Erica; Valenti, Valentina; Schiavon, Sonia; Esposito, Antonio; Di Florio, Elena; Scalia, Lorenzo; Lo Sasso, Lorenzo; Frati, Giacomo; Zoccai, Giuseppe Biondi; Versaci, Francesco; Sciarretta, Sebastiano. - In: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. - ISSN 0160-2446. - (2025). [10.1097/fjc.0000000000001755]
Current challenges for the diagnosis of HFpEF and possible simplification of the diagnostic approach
Spadafora, Luigi;Sarto, Gianmarco;Forte, Maurizio;Simeone, Beatrice;Valenti, Valentina;Schiavon, Sonia;Di Florio, Elena;Frati, Giacomo;Zoccai, Giuseppe Biondi;Sciarretta, Sebastiano
2025
Abstract
Heart failure with preserved ejection fraction (HFpEF) is a prevalent and multifaceted clinical syndrome, often underdiagnosed due to its heterogeneous presentation and overlapping comorbidities. Recent randomized trials have demonstrated the efficacy of sodium-glucose co-transporter 2 (SGLT2) inhibitors in reducing heart failure hospitalizations and cardiovascular mortality. In this review, we analyze the main challenges of HFpEF diagnosis and discuss current diagnostic algorithms. Based on recent evidence and recommendations, we propose a possible way to simplify and accelerate the diagnostic process of HFpEF, to support an early initiation of disease-modifying therapies. An interactive web-based version of the proposed algorithm is available at www.hfpefdiagnosis.com for research or exploratory purposes.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


